Histopathology in Barrett Esophagus and Barrett Esophagus-Related Dysplasia

키워드

참고문헌 (63)

1. de Jonge PJ, "Barrett’s oesophagus:epidemiology, cancer risk and implications for management", Gut, 63, pp.191~202 (2014)
2. Ishimura N, "Questionnaire-based survey conducted in 2011 concerning endoscopic management of Barrett’s esophagus in East Asian countries", Digestion, 86, pp.136~146 (2012)
3. Wang KK, "Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus", Am J Gastroenterol, 103, pp.788~797 (2008)
4. American Gastroenterological Association, "American Gastroenterological Association medical position statement on the management of Barrett’s esophagus", Gastroenterology, 140, pp.1084~1091 (2011)
5. Ogiya K, "Lower esophageal palisade vessels and the definition of Barrett’s esophagus", Dis Esophagus, 21, pp.645~649 (2008)
6. Playford RJ, "New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett’s oesophagus", Gut, 55, pp.442~ (2006)
7. Fitzgerald RC, "British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus", Gut, 63, pp.7~42 (2014)
8. Harrison R, "Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies", Am J Gastroenterol, 102, pp.1154~1161 (2007)
9. Gatenby PA, "Relevance of the detection of intestinal metaplasia in non-dysplastic columnarlined oesophagus", Scand J Gastroenterol, 43, pp.524~530 (2008)
10. Liu W, "Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium", Am J Gastroenterol, 104, pp.816~824 (2009)
11. Hahn HP, "Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus", Am J Surg Pathol, 33, pp.1006~1015 (2009)
12. Chaves P, "Gastric and intestinal differentiation in Barrett’s metaplasia and associated adenocarcinoma", Dis Esophagus, 18, pp.383~387 (2005)
13. Takubo K, "Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma", Hum Pathol, 40, pp.65~74 (2009)
14. Kelty CJ, "Barrett’s oesophagus: intestinal metaplasia is not essential for cancer risk", Scand J Gastroenterol, 42, pp.1271~1274 (2007)
15. Chandrasoma P, "Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma", Am J Surg Pathol, 36, pp.1~7 (2012)
16. Westerhoff M, "Effects of dropping the requirement for goblet cells from the diagnosis of Barrett’s esophagus", Clin Gastroenterol Hepatol, 10, pp.1232~1236 (2012)
17. Srivastava A, "Morphologic features are useful in distinguishing Barrett esophagus from carditis with intestinal metaplasia", Am J Surg Pathol, 31, pp.1733~1741 (2007)
18. Glickman JN, "Morphology of the cardia and significance of carditis in pediatric patients", Am J Surg Pathol, 26, pp.1032~1039 (2002)
19. Takubo K, "Ducts of esophageal glands proper and paneth cells in Barrett’s esophagus: frequency in biopsy specimens", Pathology, 27, pp.315~317 (1995)
20. Riddell RH, "Definition of Barrett’s esophagus: time for a rethink:is intestinal metaplasia dead?", Am J Gastroenterol, 104, pp.2588~2594 (2009)
21. Schlemper RJ, "The Vienna classification of gastrointestinal epithelial neoplasia", Gut, 47, pp.251~255 (2000)
22. Downs-Kelly E, "Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett’s esophagus biopsies", Am J Gastroenterol, 103, pp.2333~2340 (2008)
23. Takubo K, "Histopathological diagnosis of adenocarcinoma in Barrett’s esophagus", Dig Endosc (2013)[DOI]
24. Skacel M, "The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression", Am J Gastroenterol, 95, pp.3383~3387 (2000)
25. Curvers WL, "Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated", Am J Gastroenterol, 105, pp.1523~1530 (2010)
26. Lomo LC, "Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett’s esophagus cohort", Am J Surg Pathol, 30, pp.423~435 (2006)
27. Coco DP, "Interobserver variability in the diagnosis of crypt dysplasia in Barrett esophagus", Am J Surg Pathol, 35, pp.45~54 (2011)
28. Mahajan D, "Grading of gastric foveolar-type dysplasia in Barrett’s esophagus", Mod Pathol, 23, pp.1~11 (2010)
29. Patil DT, "Distinguishing Barrett gastric foveolar dysplasia from reactive cardiac mucosa in gastroesophageal reflux disease", Hum Pathol, 44, pp.1146~1153 (2013)
30. Zhu W, "A histologically defined subset of high-grade dysplasia in Barrett mucosa is predictive of associated carcinoma", Am J Clin Pathol, 132, pp.94~100 (2009)
31. Patil DT, "Prediction of adenocarcinoma in esophagectomy specimens based upon analysis of preresection biopsies of Barrett esophagus with at least high-grade dysplasia: a comparison of 2 systems", Am J Surg Pathol, 36, pp.134~141 (2012)
32. Varghese S, "Identification and clinical implementation of biomarkers for Barrett’s esophagus", Gastroenterology, 142, pp.435~441 (2012)
33. Appelman HD, "The esophageal mucosa and submucosa: immunohistology in GERD and Barrett’s esophagus", Ann N Y Acad Sci, 1300, pp.144~165 (2013)
34. Kastelein F, "Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett’s oesophagus", Gut, 62, pp.1676~1683 (2013)
35. Kaye PV, "Barrett’s dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry", Histopathology, 54, pp.699~712 (2009)
36. Kaye PV, "Novel staining pattern of p53 in Barrett’s dysplasia: the absent pattern", Histopathology, 57, pp.933~935 (2010)
37. Shi XY, "p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus", Appl Immunohistochem Mol Morphol, 16, pp.447~452 (2008)
38. Dorer R, "AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett’s esophagus, ulcerative colitis, and Crohn’s disease", Am J Surg Pathol, 30, pp.871~877 (2006)
39. Scheil-Bertram S, "Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett’s esophagus", Mod Pathol, 21, pp.961~967 (2008)
40. Lisovsky M, "Expression of alpha-methylacylcoenzyme A racemase in dysplastic Barrett’s epithelium", Hum Pathol, 37, pp.1601~1606 (2006)
41. Kastelein F, "Value of alpha-methylacyl-CoA racemase immunochemistry for predicting neoplastic progression in Barrett’s oesophagus", Histopathology, 63, pp.630~639 (2013)
42. Sonwalkar SA, "A study of indefinite for dysplasia in Barrett’s oesophagus: reproducibility of diagnosis, clinical outcomes and predicting progression with AMACR (alpha-methylacyl-CoA-racemase)", Histopathology, 56, pp.900~907 (2010)
43. Lewis CJ, "Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett’s esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies", Surg Endosc, 25, pp.2564~2569 (2011)
44. Prasad GA, "Utility of biomarkers in prediction of response to ablative therapy in Barrett’s esophagus", Gastroenterology, 135, pp.370~379 (2008)
45. Ong CA, "Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma", J Clin Oncol, 31, pp.1576~1582 (2013)
46. Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
47. Rubio CA, "Musculo-fibrous anomaly in Barrett’s mucosa with dysplasia", Am J Surg Pathol, 12, pp.885~889 (1988)
48. Takubo K, "Double muscularis mucosae in Barrett’s esophagus", Hum Pathol, 22, pp.1158~1161 (1991)
49. Nishimaki T, "Chronic esophagitis and subsequent morphological changes of the esophageal mucosa in Barrett’s esophagus: a histological study of esophagectomy specimens", Surg Today, 24, pp.203~209 (1994)
50. Barbour AP, "Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors", Ann Surg Oncol, 17, pp.2494~2502 (2010)
51. Abraham SC, "Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma", Am J Surg Pathol, 31, pp.1719~1725 (2007)
52. Kaneshiro DK, "Clinical significance of the duplicated muscularis mucosae in Barrett esophagusrelated superficial adenocarcinoma", Am J Surg Pathol, 35, pp.697~700 (2011)
53. Mandal RV, "Effect of tumor characteristics and duplication of the muscularis mucosae on the endoscopic staging of superficial Barrett esophagus-related neoplasia", Am J Surg Pathol, 33, pp.620~625 (2009)
54. Lewis JT, "Muscularis mucosae duplication and the musculo-fibrous anomaly in endoscopic mucosal resections for barrett esophagus: implications for staging of adenocarcinoma", Am J Surg Pathol, 32, pp.566~571 (2008)
55. Hahn HP, "Vascular and lymphatic properties of the superficial and deep lamina propria in Barrett esophagus", Am J Surg Pathol, 32, pp.1454~1461 (2008)
56. Estrella JS, "Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma", Am J Surg Pathol, 35, pp.1045~1053 (2011)
57. Vieth M, "Pathology of early upper GI cancers", Best Pract Res Clin Gastroenterol, 19, pp.857~869 (2005)
58. Larghi A, "Long-term follow-up of complete Barrett’s eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma", Endoscopy, 39, pp.1086~1091 (2007)
59. Manner H, "Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion", Clin Gastroenterol Hepatol, 11, pp.630~635 (2013)
60. Lee JH, "The presence of a micropapillary component predicts aggressive behaviour in early and advanced gastric adenocarcinomas", Pathology, 42, pp.560~563 (2010)
61. Eom DW, "Gastric micropapillary carcinoma:a distinct subtype with a significantly worse prognosis in TNM stages I and II", Am J Surg Pathol, 35, pp.84~91 (2011)
62. Ushiku T, "Gastric carcinoma with invasive micropapillary pattern and its association with lymph node metastasis", Histopathology, 59, pp.1081~1089 (2011)
63. Brown M, "Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro-oesophageal junction cancers", Histopathology, 56, pp.893~899 (2010)

관련 논문AI추천